Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioLife Solutions, Inc.    BLFS

BIOLIFE SOLUTIONS, INC.

(BLFS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BIOLIFE SOLUTIONS INC : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2020 | 05:27pm EDT

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an O?-Balance Sheet Arrangement of a Registrant.

Pursuant to the Paycheck Protection Program (the "PPP") guidelines originally established by the U.S. federal government as part of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, BioLife Solutions, Inc. (the "Company") determined that it met the eligibility requirements and determined to apply for relief to support its ability to maintain its employees' compensation and avoid having to layoff or furlough any of its employees. As such, on April 20, 2020, the Company received $2,175,320 in support (the "PPP Loan") from the PPP. The PPP Loan is unsecured and is evidenced by a note in favor of Silicon Valley Bank (the "Lender") as the lender (the "Note"), and is governed by a Loan Agreement with the Lender (the "Loan Agreement").

Because the U.S. government subsequently changed its position and guidelines related to the PPP and publicly traded companies, the Company intends to repay the loan on or before May 7, 2020. Prior to receiving the PPP Loan, the Company had determined to reduce the compensation of its officers and directors by twenty-five percent (25%), reduce the compensation of other staff members and implement other cost reductions. At this time, the Company has no intent to layoff or furlough any of its employees.

The interest rate on the Note is 1.0% per annum. Payments of principal and interest are deferred for 180 days from the date of the Note (the deferral period). The Paycheck Protection Program provides a mechanism for forgiveness of up to the full amount borrowed as long as the Company uses the loan proceeds during the eight-week period after the loan origination for eligible purposes, including U.S. payroll costs, certain benefits costs, rent and utilities costs, and maintains its employment and compensation levels, subject to certain other requirements and limitations. The amount of loan forgiveness is subject to reduction, among other reasons, if the Company terminates employees or reduces salaries or wages during the eight-week period. Any unforgiven portion of the PPP Loan is payable over a two-year term, with payments deferred during the deferral period. The Company is permitted to prepay the Note at any time without payment of any premium. The Note contains customary events of default, including, among others, those relating to failure to make a payment, bankruptcy, material defaults on other indebtedness, breaches of representations, and material adverse changes.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOLIFE SOLUTIONS, INC.
05/29BIOLIFE : Management's Discussion and Analysis of Financial Condition and Result..
AQ
05/27BIOLIFE SOLUTIONS INC : Unregistered Sale of Equity Securities, Financial Statem..
AQ
05/18BIOLIFE SOLUTIONS INC : Change in Directors or Principal Officers (form 8-K)
AQ
05/15BIOLIFE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
05/14BIOLIFE SOLUTIONS INC : Results of Operations and Financial Condition, Other Eve..
AQ
05/11BIOLIFE SOLUTIONS INC : Other Events (form 8-K)
AQ
04/30BIOLIFE SOLUTIONS INC : Non-Reliance on Previous Financials, Audits or Interim R..
AQ
04/24BIOLIFE : Among The Americas' Fastest Growing Companies!
PU
04/24BIOLIFE SOLUTIONS INC : Creation of a Direct Financial Obligation or an Obligati..
AQ
03/16BIOLIFE SOLUTIONS INC : Other Events (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 44,5 M - -
Net income 2020 15,4 M - -
Net cash 2020 11,0 M - -
P/E ratio 2020 28,2x
Yield 2020 -
Capitalization 428 M 428 M -
EV / Sales 2019
EV / Sales 2020 9,36x
Nbr of Employees -
Free-Float 77,0%
Chart BIOLIFE SOLUTIONS, INC.
Duration : Period :
BioLife Solutions, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOLIFE SOLUTIONS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 21,25 $
Last Close Price 16,45 $
Spread / Highest target 52,0%
Spread / Average Target 29,2%
Spread / Lowest Target 3,34%
EPS Revisions
Managers
NameTitle
Michael P. Rice President, Chief Executive Officer & Director
Raymond Wayne Cohen Chairman
Roderick de Greef Secretary, Chief Operating & Financial Officer
Aby J. Mathew Chief Scientific Officer & Executive VP
Andrew G. Hinson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOLIFE SOLUTIONS, INC.1.67%428
MEDTRONIC PLC-13.11%132 203
BAXTER INTERNATIONAL INC.7.64%45 800
HOYA CORPORATION-3.25%35 178
DEXCOM, INC.72.95%34 935
TERUMO CORPORATION8.88%29 547